Canine pancreatitis injectable lands U.S. distributionMay 18, 2023Panoquell-CA1’s active ingredient, fuzapladib sodium, has been approved for canine use in Japan since 2018.
Education Center - SponsoredWhy Some Dogs Keep Seizing: Understanding and Managing Refractory Epilepsyby • PRN PharmacalThe severe impact of drug-resistant epilepsy highlights the importance of aiming for complete seizure control in all dogs experiencing seizures. It's crucial to enhance our understanding of the reasons behind drug resistance and how they relate to various causes, progression of the disease, and affected breeds.
Canine pancreatitis injectable OKed by FDANovember 21, 2022Panoquell-CA1 has been granted conditional approval from the U.S. Food and Drug Administration (FDA) for the management of clinical signs associated with acute onset of pancreatitis in canines.
Clinical trial aims to treat canine pancreatitisFebruary 6, 2020ISK and AlcheraBio are seeking clinics to serve as clinical investigator sites to explore treatment options for patients diagnosed with acute canine pancreatitis (ACP).